Hong Kong: Doubling Down on Clinical Research
Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research…
Company information:
Ming Wai Lau Centre for Reparative Medicine is established to further accelerate research in stem cell biology, biomedical engineering, biotechnology, and regenerative medicine at Karolinska Institutet. By building a front line technology focused hub in Hong Kong, Karolinska Institutet can further strengthen the scientific interactions between KI and the Hong Kong and Chinese scientific communities.
Address: 6F, Building 15W, Hong Kong Science Park, Shatin, New Territories, Hong Kong
Tel.: +852 2624 3807
Website: http://ki.se/en/research/about-ming-wai-lau-centre-for-reparative-medicine
Email: emily.ip@ki.se (Head of Administration)
Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research…
Albert Wong of the Hong Kong Science and Technology Parks Corporation (HKSTP) outlines how Hong Kong has developed as an innovation hub, building on its established areas of finance and…
Novartis, one of the world’s largest biopharma companies, has secured approval and market access for two of its most advanced cell and gene treatments in Hong Kong. The firm’s territory…
Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and…
One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and…
Established in 2017 as a spin-off from Lee’s Pharmaceutical, Zhaoke Ophthalmology is aiming to be a global player in the ophthalmology field, building on its strong footprint in China and…
Serial entrepreneur Danny Yeung highlights the work of his Hong Kong-based genomics-driven firm Prenetics in prevention, early detection and targeted therapy. Having recently announced a USD 200 million joint venture…
Since first allowing pre-revenue biotechs to list in 2018, the Hong Kong stock exchange has welcomed 59 such companies and is now a leading vehicle for allowing Chinese biopharma to…
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) represents the interests of the global R&D-based biopharmaceutical industry in Hong Kong and Macau. Senior Executive Director Sabrina Chan outlines the…
AstraZeneca, the largest overseas pharmaceutical company in mainland China by sales, is also the market leader in Hong Kong and Macau, a territory overseen by General Manager Shan Wu. She…
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made…
See our Cookie Privacy Policy Here
